Nexthera Capital’s Heron Therapeutics HRTX Stock Holding History

Nexthera Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-388,623	Closed	-$9.5M	–	27
2019 Q1	$9.5M	Sell	388,623 -430,541	-53%	-$11.3M	11.53%	2
2018 Q4	$21.2M	Buy	819,164 +729,315	+812%	+$20.1M	8.76%	5
2018 Q3	$2.84M	Buy	+89,849	New	+$3.35M	0.55%	34
2018 Q2	–	Sell	-409,000	Closed	-$11.3M	–	50
2018 Q1	$11.3M	Buy	+409,000	New	+$9.28M	1.86%	18
2016 Q1	–	Sell	-23,600	Closed	-$630K	–	36
2015 Q4	$630K	Buy	+23,600	New	+$631K	0.89%	18

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Nexthera Capital's HRTX Position: Q2 2019 in Review

Nexthera Capital sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 388,623 shares — an estimated $9.5M sold.

Nexthera Capital first reported a position in HRTX in Q4 2015 and held it in 5 quarters. The position peaked at $21.2M in Q4 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

Nexthera Capital reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
Nexthera Capital sold 388,623 Heron Therapeutics shares in Q2 2019, an estimated $9.5M.
Nexthera Capital first reported a position in Heron Therapeutics in Q4 2015 and held it in 5 quarters.
Nexthera Capital's Heron Therapeutics position peaked at $21.2M in Q4 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.